A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.READ MORE

From The Journal

While providers and care systems can agree that effective patient navigation programs are essential to positive patient outcomes, there have been no standard metrics that could be used to measure the success of navigation programs and establish benchmarks for improvement. READ MORE
From April 12-13, the Community Oncology Alliance had its annual conference in National Harbor, Maryland. The conference centered on keeping patients and their needs paramount in transforming cancer care. Community oncology practices and allied professionals gathered to gain insights into how to overcome the challenges to patient care that they face. READ MORE
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition. READ MORE
As initial gene and cellular therapies come to market, debate is growing as to the best ways to evaluate the associated economic impact, specifically in the context of the shift to value-based reimbursements. READ MORE